Hiroaki Suga

17.1k total citations · 1 hit paper
349 papers, 13.2k citations indexed

About

Hiroaki Suga is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Hiroaki Suga has authored 349 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 317 papers in Molecular Biology, 49 papers in Organic Chemistry and 39 papers in Oncology. Recurrent topics in Hiroaki Suga's work include RNA and protein synthesis mechanisms (163 papers), Chemical Synthesis and Analysis (140 papers) and RNA modifications and cancer (78 papers). Hiroaki Suga is often cited by papers focused on RNA and protein synthesis mechanisms (163 papers), Chemical Synthesis and Analysis (140 papers) and RNA modifications and cancer (78 papers). Hiroaki Suga collaborates with scholars based in Japan, United States and United Kingdom. Hiroaki Suga's co-authors include Yuki Goto, Takayuki Katoh, Hiroshi Murakami, Alexander A. Vinogradov, Toby Passioura, Atsushi Ohta, Kristina Smith, Yizhen Yin, Takashi Kawakami and Jumpei Morimoto and has published in prestigious journals such as Nature, Cell and Chemical Reviews.

In The Last Decade

Hiroaki Suga

340 papers receiving 12.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges

2019 574 citations Yizhen Yin, Hiroaki Suga et al. Journal of the American Chemical Society profile →

Peers

Countries citing papers authored by Hiroaki Suga

Since Specialization

Citations

This map shows the geographic impact of Hiroaki Suga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Suga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Suga more than expected).

Fields of papers citing papers by Hiroaki Suga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Suga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Suga. The network helps show where Hiroaki Suga may publish in the future.

Co-authorship network of co-authors of Hiroaki Suga

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Suga. A scholar is included among the top collaborators of Hiroaki Suga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Suga. Hiroaki Suga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of selective nanomolar cyclic peptide ligands as GBA1 enzyme stabilisers 2025 ·RSC Chemical Biology ·(unknown), (unknown), María Pía Ferraz, (unknown), Toby Passioura, Hiroaki Suga, Seino A. K. Jongkees, Marta Artola	2
2	Diversity Scale of Library Matters: Impact of mRNA Library Diversity Scales on the Discovery of Macrocyclic Peptides Targeting a Protein by the RaPID System 2025 ·ACS Central Science ·(unknown), Yi Li, Naohiro Terasaka, Haruo Aikawa, Hiroaki Suga	0
3	A super versatile flexizyme system with phenol esters for genetic code reprogramming 2025 ·Nature Communications ·(unknown), Takayuki Katoh, (unknown), Hiroaki Suga	1
4	Cyclic β2,3-amino acids improve the serum stability of macrocyclic peptide inhibitors targeting the SARS-CoV-2 main protease 2024 ·Bulletin of the Chemical Society of Japan ·Takashi Miura, Tika R. Malla, Lennart Brewitz, Anthony Tumber, E. Salah, KangJu Lee, Naohiro Terasaka, David Owen, Claire Strain‐Damerell, Petra Lukacik, Martin Walsh, Akane Kawamura, Christopher J. Schofield, Takayuki Katoh, Hiroaki Suga	12
5	De Novo Discovery of Pseudo‐Natural Prenylated Macrocyclic Peptide Ligands 2024 ·Angewandte Chemie ·(unknown), Dinh Thanh Nguyen, Keisuke Hamada, (unknown), Chikako Okada, Masahiro Okada, Ikuro Abe, Toru Sengoku, Yuki Goto, Hiroaki Suga	1
6	PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination 2024 ·Cancer Immunology Research ·(unknown), (unknown), (unknown), (unknown), Matteo Ponzo, (unknown), Emiko Mihara, Atsushi Kumanogoh, Hiroaki Suga, Junichi Takagi, Luca Tamagnone, Enrico Giraudo	2
7	Oxidation-guided and collision-induced linearization assists de novo sequencing of thioether macrocyclic peptides 2024 ·Chemical Communications ·(unknown), Yuki Goto, Yutaro Saito, Hiroaki Suga, Jumpei Morimoto, Shinsuke Sando	1
8	A comprehensive analysis of translational misdecoding pattern and its implication on genetic code evolution 2023 ·Nucleic Acids Research ·Takayuki Katoh, Hiroaki Suga	4
9	Inner residues of macrothiolactone in autoinducer peptides I/IV circumvent spontaneous S -to- O acyl transfer to the upstream serine residue 2022 ·RSC Chemical Biology ·Masanobu Nagano, Satoshi Ishida, Hiroaki Suga	1
10	LimF is a versatile prenyltransferase for histidine-C-geranylation on diverse non-natural substrates 2022 ·Nature Catalysis ·(unknown), Keisuke Hamada, Dinh Thanh Nguyen, (unknown), Masayuki Satake, Shunsuke Kobayashi, Chikako Okada, Kazuhiro Ogata, Masahiro Okada, Toru Sengoku, Yuki Goto, Hiroaki Suga	31
11	De novo Fc-based receptor dimerizers differentially modulate PlexinB1 function 2022 ·Structure ·(unknown), Kyoko Matoba, Mika Hirose, (unknown), Yukiko Matsunaga, Keitaro Yamashita, Kunio Hirata, Masaki Yamamoto, Takao Arimori, Hiroaki Suga, Junichi Takagi	9
12	Potent De Novo Macrocyclic Peptides That Inhibit O‐GlcNAc Transferase through an Allosteric Mechanism 2022 ·Angewandte Chemie ·Matthew G. Alteen, Hayden Peacock, Richard W. Meek, (unknown), Sha Zhu, G.J. Davies, Hiroaki Suga, David J. Vocadlo	2
13	Lasso-grafting of macrocyclic peptide pharmacophores yields multi-functional proteins 2021 ·Nature Communications ·Emiko Mihara, Satoshi Watanabe, (unknown), (unknown), Kyoko Matoba, (unknown), Rumit Maini, Yizhen Yin, Katsuya Sakai, Takao Arimori, Kunio Matsumoto, Hiroaki Suga, Junichi Takagi	27
14	Structure–activity relationship of ipglycermide binding to phosphoglycerate mutases 2021 ·Journal of Biological Chemistry ·Mareike M. Wiedmann, Patricia Dranchak, Mahesh Aitha, (unknown), (unknown), M.M. Kashipathy, (unknown), Laurence Lamy, Joseph M. Rogers, Dingyin Tao, K.P. Battaile, Ganesha Rai, Scott Lovell, Hiroaki Suga, James Inglese	6
15	In vivo modulation of ubiquitin chains by N -methylated non-proteinogenic cyclic peptides 2020 ·RSC Chemical Biology ·Joseph M. Rogers, (unknown), (unknown), Ganga B. Vamisetti, Ido Livneh, Uri Barash, Israël Vlodavsky, Aaron Ciechanover, David Fushman, Hiroaki Suga, Ashraf Brik	22
16	Design, Synthesis, and Conformation–Activity Study of Unnatural Bridged Bicyclic Depsipeptides as Highly Potent Hypoxia Inducible Factor-1 Inhibitors and Antitumor Agents 2020 ·Journal of Medicinal Chemistry ·(unknown), Masanobu Nagano, Masahiro Ebihara, Tasuku Hirayama, (unknown), Hiroaki Suga, Hideko Nagasawa	11
17	Cyclic peptides can engage a single binding pocket through highly divergent modes 2020 ·Proceedings of the National Academy of Sciences ·Karishma Patel, Louise J. Walport, J.L. Walshe, (unknown), Jason K. K. Low, (unknown), (unknown), Ana P. G. Silva, Lorna Wilkinson‐White, Alexander Norman, Charlotte Franck, Jacqueline M. Matthews, J.M. Guss, Richard J. Payne, Toby Passioura, Hiroaki Suga, Joel P. Mackay	32
18	Structural basis for gating mechanisms of a eukaryotic P-glycoprotein homolog 2014 ·Proceedings of the National Academy of Sciences ·Atsushi Kodan, Tomohiro Yamaguchi, Toru Nakatsu, (unknown), Christopher J. Hipolito, (unknown), (unknown), (unknown), Bunta Watanabe, Jun Hiratake, Yasuhisa Kimura, Hiroaki Suga, Kazumitsu Ueda, Hiroaki Kato	148
19	Discovery of Macrocyclic Peptides Armed with a Mechanism‐Based Warhead: Isoform‐Selective Inhibition of Human Deacetylase SIRT2 2012 ·Angewandte Chemie ·Jumpei Morimoto, Yuuki Hayashi, Hiroaki Suga	23
20	Reduction of an Aldehyde by a NADH/Zn ²⁺ -Dependent Redox Active Ribozyme 2004 ·Journal of the American Chemical Society ·Shinya Tsukiji, Swetansu Pattnaik, Hiroaki Suga	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact